{"disease":{"id":"extrapyramidal-disease","name":"Extrapyramidal disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"trihexyphenidyl-hydrochloride","indication_name":"Extrapyramidal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cogentin","indication_name":"Extrapyramidal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cogentin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"trihexyphenidyl","indication_name":"Extrapyramidal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Artane","generic_name":"TRIHEXYPHENIDYL","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"trihexyphenidyl","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"procyclidine","indication_name":"Extrapyramidal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kemadrine","generic_name":"PROCYCLIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"biperiden","indication_name":"Extrapyramidal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Akineton","generic_name":"BIPERIDEN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"amantadine","indication_name":"Extrapyramidal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gocovri","generic_name":"AMANTADINE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"benzatropine","indication_name":"Extrapyramidal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cogentin","generic_name":"benzatropine","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Anticholinergic","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"gocovri","indication_name":"Extrapyramidal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GOCOVRI","company_name":"Oregon Health and Science University","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"amantadin","indication_name":"Extrapyramidal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amantadin","company_name":"Centre Hospitalier Universitaire de Nice","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}